Evidence map›Paper›PMID 31691549›Full record

ArticleCancer medicine2019

Clinical characteristics, diagnosis, treatment, and prognostic factors of pulmonary mucosa-associated lymphoid tissue-derived lymphoma.

Lin Wang, Guanzhi Ye, Zhonghe Liu, Lin Shi, Cheng Zhan, Jie Gu, Rongkui Luo, Zongwu Lin, Di Ge, Qun Wang

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 42 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
  6. Characteristics of pulmonary lymphoma on baselineQuantitative imaging in medicine and surgery · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Primary pulmonary lymphoma: a surgical series.Indian journal of thoracic and cardiovascular surgery · 2025
    Article
  12. [Research Progress of Pulmonary Extranodal Marginal Zone Lymphoma].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Lin WangDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Guanzhi YeDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhonghe LiuDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Lin ShiDepartment of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Cheng ZhanDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID 0000-0001-8745-9276
Jie GuDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Rongkui LuoDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Zongwu LinDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID 0000-0002-8868-4405
Di GeDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID 0000-0003-4230-5120
Qun WangDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID 0000-0003-4853-1727
Sun Yat-sen University · CN

Funding

National Nature Science Foundation of China 81572295National Nature Science Foundation of China 81800034Youth Foundation of Zhongshan Hospital 2018ZSQN01Youth Foundation of Zhongshan Hospital 2019ZSQN34
6 · The paper itself

Abstract

Primary pulmonary mucosa-associated lymphoid tissue-derived (MALT) lymphoma is a rare disease with a favorable prognosis. However, its clinical characteristics, diagnosis, treatment, and prognoses remain unclear. We retrospectively analyzed 80 patients with pathologically confirmed MALT lymphoma from 2006 to 2018. The clinical characteristics, diagnosis, treatments, and prognoses of all the 80 patients were recorded. Patients were stratified into surgery and biopsy groups, respectively, to evaluate the role of surgery in the diagnosis and treatment of MALT lymphoma. The prognoses were compared between different clinical characteristics and treatments. Pathological diagnoses were confirmed by surgery, bronchoscopy, and percutaneous biopsy. Thirty patients were treated by surgery. While MALT lymphoma was only diagnosed by bronchofiberoscopy or bercutaneous biopsy in four of 18 patients in the surgery group who underwent the procedure. Six patients received adjuvant chemotherapy and one patient received involved-field radiotherapy in surgery group. Thirty-one patients were treated with chemotherapy alone, one patient was treated with radiotherapy, one patient received only symptomatic and supportive treatment, and waiting and watching without treatment were recommended in 17 patients in biopsy group. Eight patients died during follow-up and the 5-year survival rate was 87.1%. Tumor number, treatment, and age were prognostic factors for overall survival (OS), but age was the only independent prognostic factor according to multivariate analysis. While, tumor number was the only prognostic factor in the analysis about progression-free survival (PFS). No significant difference was found in OS or PFS between patients treated with and without surgical resection. MALT lymphoma is an indolent disease with favorable treatment outcome. Tumor number is associated with PFS and age is the only significant prognostic factor for pulmonary MALT lymphoma patients because of its indolent nature, but surgery still plays an important role in the diagnosis and treatment of MALT lymphoma.

Indexed as

AdultAgedBiomarkersBiopsyClinical Decision-MakingCombined Modality TherapyDecision TreesDisease ManagementFemaleHumansImmunohistochemistryImmunophenotypingKaplan-Meier EstimateLung NeoplasmsLymphoma, B-Cell, Marginal ZoneMaleBiomarkerschemotherapyMALT lymphomaprognosispulmonary lymphomathoracic surgery

Identifiers

PMID31691549
PMCPMC6912039
OpenAlexW2987005526

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.